Quebec-based Immunotec posted a 31 percent increase in U.S. sales for the quarter ended July 31, primarily due to a 37 percent jump in new U.S. consultants and customers. By contrast, sponsoring activities in Mexico fell 20.6 percent from a year ago, as the market continues to adjust to a 16 percent value-added tax introduced by Immunotec in October 2014.
Quarterly revenue totaled $16.8 million, comparable to $16.9 million a year ago. In the first three quarters of the year, cumulative revenue increased 4.3 percent versus the same period in 2014.
Adjusted EBITDA also remained flat at $1.1 million, the publicly traded company reported. Net profit was $910,505, compared to a loss of $3.3 million a year ago.